Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Vor Biopharma Inc VOR

Healthcare Biotechnology
Vor Biopharma Inc. is a clinical-stage cell and genome engineering therapy company. The Company is engaged in combining a novel patient engineering approach with targeted therapies to provide solutions for patients suffering from hematological malignancies. Its proprietary platform leverages expertise in hematopoietic stem cell (HSC) biology, genome engineering and targeted therapy development... see more

Recent & Breaking News (NDAQ:VOR)

Vor Bio Doses First AML Patient with VCAR33 (ALLO) and Provides Corporate Update

GlobeNewswire January 17, 2024

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire December 21, 2023

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire December 1, 2023

Vor Bio to Participate in the JMP Securities Hematology and Oncology Summit

GlobeNewswire November 27, 2023

Vor Bio Presents Positive Data Update on Trem-cel at HSCT² Conference

GlobeNewswire November 9, 2023

Vor Bio Reports Third Quarter 2023 Financial Results and Provides Company Update

GlobeNewswire November 7, 2023

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire November 3, 2023

Vor Bio to Participate in Upcoming Investor Conferences

GlobeNewswire November 3, 2023

Multiple Clinical and Preclinical Presentations at ASH 2023 Highlight Vor Bio's Novel eHSC and CAR-T Platform

GlobeNewswire November 2, 2023

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire October 3, 2023

Vor Bio to Participate in Upcoming Investor Conferences

GlobeNewswire September 25, 2023

Vor Bio to Participate in Upcoming Investor Conferences

GlobeNewswire August 30, 2023

Vor Bio Reports Second Quarter 2023 Financial Results and Provides Company Update

GlobeNewswire August 10, 2023

Vor Bio to Participate in the Wedbush PacGrow Healthcare Conference

GlobeNewswire August 1, 2023

Successful Primary Engraftment of Trem-cel in First Five AML Patients Demonstrates Promise of Vor Bio's Platform

GlobeNewswire June 9, 2023

Vor Bio to Participate in the Goldman Sachs Healthcare Conference

GlobeNewswire June 5, 2023

Vor Bio Reports First Quarter 2023 Financial Results and Provides Company Update

GlobeNewswire May 11, 2023

Vor Bio to Participate in Upcoming Investor Conferences

GlobeNewswire April 18, 2023

Vor Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Company Update

GlobeNewswire March 23, 2023

Vor Bio to Participate in Upcoming Investor Conferences

GlobeNewswire February 21, 2023